• Indi Molecular

  Led · Series A · Jul 2017

  Indi Molecular is developing a novel class of synthetic binders called protein catalyzed capture agents (PCCs) that combine antibody-like specificity with small‑molecule chemical properties. PCCs are low‑molecular‑weight, highly specific binders the company positions for use across research tools, diagnostics and PET imaging. The company has demonstrated utility of PCC binders in multiple applications and has collaborated with partners including the Bill and Melinda Gates Foundation, the U.S. Department of Defense and leading healthcare companies. Indi Molecular plans to use the new funding to establish a high‑throughput PCC discovery platform. It also intends to advance existing leads in PET immuno‑oncology imaging toward the clinical stage. The company was founded in 2013 and is based in Culver City, CA. Indi Molecular develops protein-catalyzed capture (PCC) agents: chemically synthesized short-peptide molecules intended to replicate or improve upon monoclonal antibody binding. PCCs are created using click chemistry in collaboration with Caltech and are positioned for applications in in vivo imaging, therapeutics, in vitro diagnostics and biological tools. The company highlights advantages of PCCs including greater thermal stability, lower cost and faster development compared with monoclonal antibodies. Recent work with Caltech produced three publications demonstrating epitope targeting of Akt2, thermally stable HIV antibody detection reagents, and a trace-level electrochemical anthrax detector; the HIV work was supported by the Bill & Melinda Gates Foundation. Indi Molecular launched as a spinout in 2013 and is headquartered in Culver City, California. The company is using funds from its seed financing to further develop PCC technology and advance its diagnostic and therapeutic applications. Indi Molecular is a Culver City, CA-based developer of a synthetic replacement for antibodies built around PCC (protein catalyzed capture) agent technology. PCCs are synthetic peptide molecules capable of binding interactions equivalent or superior to molecular antibodies. The company licensed the PCC technology from the California Institute of Technology and is developing the agents for in vivo imaging, therapeutics, in vitro diagnostics and biological tools. Indi Molecular raised $1.5M in seed funding and intends to use the proceeds to further develop its PCC platform. Previously an operating division of Integrated Diagnostics, it now operates as an independent company while maintaining ties to its parent. The company is led by CEO Albert A. Luderer, Ph.D.; its board and advisors include James Heath, Lee Hood, Douglas C. Fisher, K. Barry Sharpless and co-founder Michael Phelps, and the company’s laboratory will serve as its headquarters.

No current team members are available.